Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Aims To Duplicate Januvia Launch Success In 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Launches for Janumet, Arcoxia and Emend IV are keys to continuing the momentum of firm’s turnaround plan, CEO Clark says.

You may also be interested in...



Merck Gains Positive Opinion For Januvia In EU

Firm expects final EU clearance in early April.

Merck Gains Positive Opinion For Januvia In EU

Firm expects final EU clearance in early April.

Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review

FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.

Related Content

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel